- Fund Type: Open-End Fund
- Objective: Sector Fund-Technology
- Asset Class: Equity
- Geographic Focus: Euro Countries
Raiffeisen-Technologie-Aktien
+ Add to WatchlistRTECIVA:AV
111.13 EUR 0.57 0.51%As of 00:59:30 ET on 05/22/2013.
Snapshot for Raiffeisen-Technologie-Aktien (RTECIVA)
| Year To Date: | +15.86% | 3-Month: | +10.22% | 3-Year: | - | 52-Week Range: | 81.13 - 111.70 |
|---|---|---|---|---|---|---|---|
| 1-Month: | +11.78% | 1-Year: | +34.65% | 5-Year: | - | Beta vs MXWO0IT: | 0.77 |
Fund Profile & Information for RTECIVA
Raiffeisen-Technologie-Aktien is an open-end investment fund incorporated in Austria. The Fund invests in stocks from the technology sector.
| Inception Date: | 04-01-2011 | Telephone: | +43-71170-3952 |
|---|---|---|---|
| Managers: | - | ||
| Web Site: | www.rcm.at | ||
Fundamentals for RTECIVA
| NAV | (on 2013-05-22) 111.13 |
|---|---|
| Assets (M) | (on 2013-05-22) 21.31 |
| Fund Leveraged | N |
| Minimum Investment | - |
| Minimum Subsequent Investment | - |
Dividends for RTECIVA
No dividends reported
Fees & Expenses for RTECIVA
| Front Load | - |
|---|---|
| Back Load | - |
| Current Mgmt Fee | - |
| Redemption Fee | - |
| 12b1 Fee | - |
| Expense Ratio | 1.19 |
Top Fund Holdings for RTECIVA
Filing Date: 01/31/2013| Name | Position | Value | % of Total |
|---|---|---|---|
| Oracle Corp | 50,000 | 1,303,659 | 6.933% |
| Apple Inc | 3,180 | 1,070,577 | 5.693% |
| International Business Machine | 7,100 | 1,064,882 | 5.663% |
| Intel Corp | 67,000 | 1,055,153 | 5.611% |
| Microsoft Corp | 46,800 | 960,522 | 5.108% |
| Google Inc | 1,480 | 822,188 | 4.373% |
| Temenos Group AG | 52,000 | 798,094 | 4.244% |
| Cisco Systems Inc | 50,000 | 758,318 | 4.033% |
| Samsung Electronics Co Ltd | 700 | 684,348 | 3.639% |
| QUALCOMM Inc | 14,500 | 678,864 | 3.610% |
Quotes delayed, except where indicated otherwise. Mutual fund NAVs include dividends. All prices in local currency. Time is ET.
Sponsored Financial Commentaries
Advertisement
Top Forex Trading Resources
- 1
- 2
- 3
- 4
- 5
Advertisement
Advertisement
Sponsored Links
Advertisements
Rate this Page